LifeSciVC

JANUARY 16, 2024

These are incredible forecasts and CAGRs, which if we assume directionally correct, rely not only on steady growth for approved therapies but also a substantial success rate of, and continued investment in, the development pipeline. recent announcements from Merck and Sanofi for obesity and broader metabolic disease). Join the club.

Small Molecule 137

Small Molecule Trials Therapies Disease 137

The Pharma Data

JULY 27, 2021

AbbVie (NYSE: ABBV) and Calico Life Sciences today announced an extension of their leading-edge collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer. This is the second extension of the collaboration originally established in 2014.

Disease 52

Disease Science Therapies Production 52

The Pharma Data

MARCH 9, 2021

New data from 10 studies will be presented by Eli Lilly and Company (NYSE: LLY) at the upcoming virtual International Conference on Alzheimer’s & Parkinson Diseases 2021 (AD/PD 2021), March 9-14, 2021. vice president of Alzheimer’s disease development unit, Eli Lilly and Company.

Disease 40

Disease International Research Therapies 40

The Pharma Data

MARCH 2, 2021

This new collaboration builds on the positive experience from previous partnerships with Gubra and combines Gubra’s proprietary streaMLine platform and expertise in obesity and peptide chemistry with Boehringer Ingelheim’s expertise in lead optimization and clinical development. population will have obesity. About Boehringer Ingelheim.

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

The Pharma Data

FEBRUARY 21, 2022

At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients.

Clinical Trials 52

Clinical Trials Small Molecule Clinical Development Disease 52

Drug Target Review

OCTOBER 1, 2024

Considering the Italian landscape, for example, it is my opinion that resources allocated by the National Recovery and Resilience Plan (PNRR) for gender equality represent a unique opportunity to aspire to achieve the sustainable development objectives set out in the 2030 Agenda.

Doctors 97

Doctors Therapies Science Pharma Companies 97

The Pharma Data

FEBRUARY 24, 2022

– Heart failure represents a significant, growing disease burden in the U.S., with more than 8 million cases expected by 2030. vice president, Clinical Development & Medical Affairs, Cardio-Metabolism & Respiratory Medicine, Boehringer Ingelheim Pharmaceuticals, Inc. Source link: [link].

FDA Approval 52

FDA Approval FDA Hospitals Trials 52